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Abstract
ATP Binding Cassette B1 (ABCB1) is a transporter with a broad substrate specificity involved in the elimination of several
carcinogens from the gut. Several polymorphic variants within the ABCB1 gene have been reported as modulators of ABCB1-
mediated transport. We investigated the impact of ABCB1 genetic variants on colorectal cancer (CRC) risk. A hybrid tagging/
functional approach was performed to select 28 single nucleotide polymorphisms (SNPs) that were genotyped in 1,321
Czech subjects, 699 CRC cases and 622 controls. In addition, six potentially functional SNPs were genotyped in 3,662
German subjects, 1,809 cases and 1,853 controls from the DACHS study. We found that three functional SNPs (rs1202168,
rs1045642 and rs868755) were associated with CRC risk in the German population. Carriers of the rs1202168_T and
rs868755_T alleles had an increased risk for CRC (Ptrend=0.016 and 0.029, respectively), while individuals bearing the
rs1045642_C allele showed a decreased risk of CRC (Ptrend=0.022). We sought to replicate the most significant results in an
independent case-control study of 3,803 subjects, 2,169 cases and 1,634 controls carried out in the North of Germany. None
of the SNPs tested were significantly associated with CRC risk in the replication study. In conclusion, in this study of about
8,800 individuals we show that ABCB1 gene polymorphisms play at best a minor role in the susceptibility to CRC.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers
diagnosed in Western countries [1,2] and its etiology involves the
interaction of genetic and environmental factors [3,4,5,6,7,8,
9,10,11]. Although the biological processes connecting lifestyle
characteristics and colorectal carcinogenesis remain unclear,
association studies analyzing the influence of dietary factors have
evidenced that, at least in part, CRC arises as a consequence of
exposure to xenobiotics taken up with food [6,12].
ATP-binding cassette (ABC) is one of the largest families of
active efflux transporters that are located mainly in tissues acting
as a barrier or having an excretory function. ABC transporters are
highly expressed in the apical membrane of enterocytes where
they mediate the efflux of a wide variety of endogenous substrates
(including sugars, amino acids, nucleotides, steroids, inorganic
ions) into the gut lumen. In addition, most of the ABC transporters
play a role in cell defense against environmental attacks generated
by xenobiotics [13].
ABCB1 expression in the human intestine increases from
proximal to distal, resulting in the highest expression levels in
the colon [14], where it is involved in the excretion of several
carcinogens from the gut into the intestinal lumen [15]. In
addition, it has been demonstrated that ABCB1 is responsible for
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32784the efflux of cooked-food mutagens [16], several tobacco-related
carcinogens [17,18,19], as well as a broad spectrum of drugs
[20,21,22,23].
The expression and activity of the ABCB1 transporter may differ
between individuals, due to either genetic polymorphisms or
pathological conditions [24] and, as a result, this might be
reflected in differences in the bioavailability of different toxins,
carcinogens and drugs [5]. Over the last decades, this hypothesis
has led to a proliferation of in vitro reports examining the
functionality of ABCB1 gene polymorphisms and the investigation
on their potential role in many diseases and cancers
[4,25,26,27,28,29,30,31]. Functional polymorphic variants of
ABCB1 have been reported in the Caucasian population. For
example Hoffmeyer and collaborators reported that the C3435T
variant (rs1045642) results in a reduced activity and expression of
the protein in the duodenum [23]. Likewise, several studies have
also focused on the association between polymorphic variants of
ABC multidrug transporters and exposure to anticancer drugs
[21,22]. Despite numerous association studies addressing the effect
of ABCB1 variants and CRC [30,31,32,33,34], limited data are
available, as most of these association studies have analyzed a
reduced number of genetic markers or have been performed in a
relatively small population.
The aim of the present work was to ascertain if genetic variants
within the ABCB1 gene influence the risk of CRC, with particular
attention to the role of putatively functional variants that have
previously been shown to be associated with cancer risk
[24,30,32,33].
Materials and Methods
Ethics statement
All participants signed an informed written consent. The study
was approved by the ethical review boards of the institutions
responsible for subject recruitment in each of the recruitment
centres. The ethical committees were the following: Ethics
Committee of the Institute of Experimental Medicine, Prague,
Czech Republic. The DACHS study was approved by the ethics
committees of the Medical Faculty at the University of Heidelberg
and of the Medical Chambers of Baden-Wu ¨rttemberg and
Rhineland-Palatinate. The North German Study (Kiel) was
approved by the ethics committees of the Medical Faculty at the
Christian-Albrechts University of Kiel and Mecklenburg- West
Pomerania (Study of Health In Pomerania).
Study populations
In this study three populations of Caucasian origin (one from
the Czech Republic and two from Germany) were investigated,
including a total of 8786 subjects. All the populations were
previously described in detail [35]. Briefly, the first case-control
study comprises 1321 subjects, 699 CRC cases and 622 controls
from the Czech Republic [36]. All participants were recruited
from six oncological and five gastroenterological departments, all
over the Czech Republic. The study was based on incident cases
with positive colonoscopic results for malignancy and with
histologically confirmed colon or rectal carcinoma. Controls were
defined as subjects who had undergone colonoscopy and whose
colonoscopic results were negative for malignancy or colorectal
adenomas. They were sampled in the same time frame as the
cases. All participants signed an informed written consent and the
design of the study was approved by the Ethical Committee of the
Institute of Experimental Medicine, Prague, Czech Republic.
The second case-control study comprises 3662 participants,
1809 cases and 1853 controls recruited from the DACHS
(Darmkrebs: Chancen der Verhu ¨tung durch Screening) study,
[37]. Cases had incident invasive CRC diagnosed between
January 2003 and March 2007. They were recruited from patients
who received in-patient treatment in a hospital of the Rhein-
Neckar-Odenwald region (Southwest Germany) due to a first
diagnosis of CRC. Controls were frequency matched according to
gender, county of residence and age and randomly selected from
lists of population registries. The DACHS study was approved by
the ethics committees of the Medical Faculty at the University of
Heidelberg and of the Medical Chambers of Baden-Wu ¨rttemberg
and Rhineland-Palatinate. All patients gave their informed written
consent to participate in this study.
In order to replicate the positive findings in the discovery set, we
also used an independent population-based case-control study in a
North German population that comprises 3803 subjects, 2169
cases and 1634 controls [38]. CRC cases were identified through
the regional cancer registry of Schleswig-Holstein or through
records of surgical departments in Northern Germany and
recruited by the POPGEN biobank. Controls were randomly
selected from population registries and also recruited by the
POPGEN biobank. Additional controls were recruited from SHIP
(Study of Health In Pomerania) in North-eastern Germany and
were cancer-free at recruitment.
SNP Selection
The entire set of common genetic variants in ABCB1 was assessed
following both tagging and functional approaches. The aim of the
SNP tagging was to identify a set of SNPs that efficiently captures all
the known common genetic variability, while the functional
approachwas used to determine the impact of potentially functional
variants within ABCB1 gene on CRC risk. The tagging was carried
out using the algorithm described by Carlson and co-workers [39].
All SNPs within the region of ABCB1 (including 5 kb upstream of
the first exon and downstream of the last exon) and with a minor
allele frequency (MAF) $5% in Caucasians (International HapMap
Project, version 21a; http://www.hapmap.org), were included.
Tagging SNPs were selected with the use of the Haploview Tagger
program (http://www.broad.mit.edu/mpg/haploview/; http://
www.broad.mit.edu/mpg/tagger/) [40,41], using pairwise tagging
with a minimum r
2 of 0.8. This resulted in a selection of 28 tagging
SNPs, with a mean r
2 of the selected SNPs withthe SNPs they tag of
0.976, meaning that our selection captures to a very high degree the
known common variability in this gene. Considering that the
genomic region of ABCB1 is characterized by high levels of linkage
disequilibrium (LD), we postulate that such SNPs are also likely to
tag any hitherto unidentified common SNPs in the gene.
In order to test the hypothesis suggesting that functional SNPs
rather than tagging SNPs might affect the ABCB1-mediated efflux
of DNA damaging substances, we selected six potentially
functional SNPs out of the 28 previously selected (rs2229109,
rs1202168, rs1045642, rs9282564, rs2214102 and rs868755), and
we genotyped them in the Czech and in the German DACHS
populations. The selection was based on previously published
results that pointed out either the functionality of ABCB1 variants
[23,42] or their association with various diseases [43,44,45].
In order to exhaustively cover all the genetic variability in the
ABCB1 locus we have checked the variants described in the 1000
genome project and we found out that 180 SNPs have not been
genotyped in in HapMap. We did not include these variants since
in Caucasians the frequency of the minor allele was either missing
or lower than the threshold of 0.05. Searching the database of
genomic variants (http://projects.tcag.ca/variation/), which is a
catalogue of structural variation in the human genome, we found
that in Caucasian there is only a rare (MAF=0.03%) copy
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genotype it. Supplementary figure S1 shows in detail the number
of SNPs and subjects genotyped in each phase. Supplementary
figure S2 shows the LD plot of the ABCB1 gene, all the SNPs at the
locus and the SNPs genotyped, while Supplementary table S1
shows the tagging SNPs selected in the study and the SNPs they
tag.
DNA extraction and genotyping
For the Czech subjects DNA was extracted from blood using
standard proteinase K digestion followed by phenol/chloroform
extraction and ethanol precipitation. German DNA samples were
isolated from peripheral blood mononuclear cells or mouthwash
using Flexigene Kit 250 (Qiagen, Valencia, CA, USA) and Qiagen
Mini Kit (Qiagen, Valencia, CA, USA), respectively. The order of
DNAs from cases and controls was randomized on PCR plates in
order to ensure that an equal number of cases and controls could
be analyzed simultaneously. All the genotyping was carried out
using Taqman (Applied Biosystems, Foster City, CA, USA) or
KASPar (KBiosciences, Hoddesdon, Hertfordshire, UK) accord-
ing to the manufacturers’ protocols. Repeated quality control
genotypes (8% of the total) showed an average concordance of
99.9%. More details on the genotyping methods can be found
elsewhere [36,46,47]. PCR plates were read on an ABI PRISM
7900HT instrument (Applied Biosystems). The genotypes of SNPs
rs2229109, rs1202168, rs1045642, rs9282564, rs2214102 partially
overlap with those used in another project for a subset of the
DACHS subjects reported here [48]. The results showed in the
present paper have not been previously reported.
Statistical Analysis
Genotype distribution was examined in the cases and control
populations. Hardy-Weinberg equilibrium was tested in the
controls by chi square test and at the a=1% level. We used
logistic regression for multivariate analyses to assess the main
effects of the genetic polymorphism on CRC risk using a log-
additive inheritance model. The most common genotype in the
controls was assigned as the reference category. All analyses were
adjusted for age and gender. Additionally, we performed a logistic
regression stratifying for the cancer site (colon versus rectum). All
statistical analyses were performed using SAS 9.2.
Since polymorphisms selected as tagging SNPs had a low level
of residual linkage disequilibrium (LD), we assumed that
haplotypes were adequately captured by our tagging SNP
approach, and we did not attempt a haplotype analysis in the
Czech population. However we performed it for the 6 SNPs
selected as functional ones. Haplotype blocks were constructed
from the control genotyping data using SNP-tool http://www.
dkfz.de/de/molgen_epidemiology/tools/SNPtool.html, [49] and
the algorithm implemented in Haploview based on confidence
bounds by Gabriel and collegues [50]. The following cut-off values
were used: MAF.5%, HWE p$0.01 and 75% of non-missing
genotypes. Maximum likelihood estimates of the haplotype
frequencies were generated with an expectation-maximization
based algorithm implemented in the PROC HAPLOTYPE
procedure of SAS. Unconditional logistic regression adjusted for
age (continuous), sex and study centre was used to calculate risk
estimates. The most frequent haplotype was set as the reference,
whereas haplotypes with a frequency below 0.05 were declared as
rare haplotypes and combined.
To evaluate the possibility of false positives, we took into
account the issue of multiple testing. SNPSpD software (http://
genepi.qimr.edu.au/general/daleN/SNPSpD), based on the use
of the spectral decomposition (SpD) of matrices of pairwise LD
between SNPs, was used to calculate the effective number of
independent markers (Meff) for multiple testing [51,52]. The p-
values were evaluated in light of the Meff value.
Results
We performed a case-control study using three nested sets of
ABCB1 SNPs in three distinct populations of Czech and German
origins. The first SNP set consisted of 28 tagging SNPs, which we
tested in 699 cases and 622 controls from the Czech Republic. The
second SNP set consisted of a subgroup of the 28 tagging SNPs,
namely six putatively functional SNPs, which we additionally typed
in a German population of 1809 cases and 1853 controls. Finally,
we replicated the best hits, namely SNPs rs1202168, rs1045642,
rs9282564, and rs868755, in up to 2169 additional cases and 1634
additional controls from North Germany. These four SNPs were
thereforetypedinallthepopulations,givingthisstudyafinalsample
size of up to 4677 cases and 4109 controls. The relevant
characteristics of the three populations are reported in table 1.
The genotype frequencies among the controls were in Hardy-
Weinberg equilibrium for all the SNPs and in all populations. The
calculated Meff value was 16. We therefore considered a study-wide
significance p-value threshold of 0.05/16=0.003.
Table 1. Population characteristics.
Czech population Cases Controls
(n=699) (n=622)
Males (%)* 397 (56.8) 336 (54.0)
Females (%) 302 (43.2) 286 (46.0)
Age (Age at Diagnosis) Median 62 56
Range 27–90 28–91
Mean (SD) 61.1 (11.0) 55.3 (13.5)
Rectal cancer (%) 38.7
Colon cancer (%) 61.3
DACHS population Cases Controls
(n=1809) (n=1853)
Males (%)* 1056 (58.4) 1095 (59.1)
Females (%) 753 (41.6) 758 (40.9)
Age (Age at Diagnosis) Median 69 70
Range 33–94 34–98
Mean (SD) 68.3 (10.4) 68.6 (10.2)
Rectal cancer (%) 39.0
Colon cancer (%) 61.0
Kiel population Cases Control
(n=2169) (n=2060)
Males (%)* 1087 (50.1) 986 (47.9)
Females (%) 1082 (49.9) 1074 (52.1)
Age (Age at Diagnosis) Median 62 65
Range 10–85 23–81
Mean (SD) 60.9 (8.8) 64.7 (10.0)
Rectal cancer (%) 51.4
Colon cancer (%) 48.6
doi:10.1371/journal.pone.0032784.t001
Polymorphisms of ABCB1 and Colon Cancer
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32784T
a
b
l
e
2
.
R
e
p
l
i
c
a
t
i
o
n
o
f
A
B
C
B
1
p
o
l
y
m
o
r
p
h
i
s
m
s
.
C
Z
E
C
H
a
p
o
p
u
l
a
t
i
o
n
D
A
C
H
S
a
p
o
p
u
l
a
t
i
o
n
K
I
E
L
a
p
o
p
u
l
a
t
i
o
n
T
o
t
a
l
a
p
o
p
u
l
a
t
i
o
n
C
z
e
c
h
p
o
p
u
l
a
t
i
o
n
D
A
C
H
S
p
o
p
u
l
a
t
i
o
n
K
I
E
L
p
o
p
u
l
a
t
i
o
n
T
o
t
a
l
p
o
p
u
l
a
t
i
o
n
C
o
n
t
r
o
l
s
C
a
s
e
s
C
o
n
t
r
o
l
s
C
a
s
e
s
C
o
n
t
r
o
l
s
C
a
s
e
s
C
o
n
t
r
o
l
s
C
a
s
e
s
O
R
(
9
5
%
C
I
)
b
p
t
r
e
n
d
O
R
(
9
5
%
C
I
)
b
p
t
r
e
n
d
O
R
(
9
5
%
C
I
)
b
p
t
r
e
n
d
O
R
(
9
5
%
C
I
)
b
p
t
r
e
n
d
r s 8 6 8 7 5 5
G
/
G
2
0
1
2
1
5
5
6
8
4
9
8
3
4
6
2
3
9
1
1
1
5
9
5
2
1
.
0
0
0
.
8
8
4
1
.
0
0
0
.
0
2
9
1
.
0
0
0
.
4
4
3
1
.
0
0
0
.
0
8
6
G
/
T
2
2
7
2
9
5
7
9
4
8
0
5
5
2
1
3
3
5
1
5
4
2
1
4
3
5
1
.
2
2
(
0
.
9
4
–
1
.
6
0
)
1
.
1
7
(
1
.
0
0
–
1
.
3
6
)
0
.
8
1
(
0
.
6
3
–
1
.
0
5
)
1
.
1
1
(
0
.
9
9
–
1
.
2
5
)
T
/
T
9
2
9
2
3
4
4
3
6
4
1
6
2
1
1
5
5
9
8
5
7
1
0
.
9
3
(
0
.
6
5
–
1
.
3
4
)
1
.
2
2
(
1
.
0
1
–
1
.
4
8
)
0
.
9
4
(
0
.
6
7
–
1
.
3
2
)
1
.
1
2
(
0
.
9
7
–
1
.
2
9
)
r s 1 2 0 2 1 6 8
C
/
C
2
0
6
2
3
1
6
4
7
5
6
8
5
5
1
7
2
6
1
4
0
4
1
5
2
5
1
.
0
0
0
.
9
1
2
1
.
0
0
0
.
0
1
6
1
.
0
0
0
.
6
1
4
1
.
0
0
0
.
2
6
3
C
/
T
2
7
4
3
2
9
8
3
5
8
8
0
7
9
5
1
0
0
1
1
9
0
4
2
2
1
0
1
.
1
1
(
0
.
8
6
–
1
.
4
3
)
1
.
2
0
(
1
.
0
4
–
1
.
4
0
)
0
.
9
6
(
0
.
8
3
–
1
.
1
1
)
1
.
0
7
(
0
.
9
8
–
1
.
1
8
)
T
/
T
1
1
2
1
1
8
3
1
8
3
4
1
2
8
4
3
5
7
7
1
4
8
1
6
0
.
9
4
(
0
.
6
7
–
1
.
3
1
)
1
.
2
3
(
1
.
0
1
–
1
.
4
8
)
0
.
9
6
(
0
.
7
9
–
1
.
1
6
)
1
.
0
6
(
0
.
9
3
–
1
.
2
0
)
r s 1 0 4 5 6 4 2
T
/
T
1
6
6
1
9
0
4
8
6
5
0
1
3
1
3
1
9
2
9
6
5
8
8
3
1
.
0
0
0
.
7
9
7
1
.
0
0
0
.
0
2
2
1
.
0
0
0
.
0
5
1
1
.
0
0
0
.
2
9
7
T
/
C
2
7
9
3
3
5
8
6
8
9
1
8
5
1
0
3
5
4
1
6
5
7
1
6
0
7
1
.
0
4
(
0
.
8
0
–
1
.
3
7
)
1
.
0
3
(
0
.
8
8
–
1
.
2
0
)
1
.
1
4
(
0
.
8
7
–
1
.
4
9
)
1
.
0
6
(
0
.
9
5
–
1
.
1
9
)
C
/
C
1
3
1
1
4
2
4
4
7
3
6
7
2
0
2
1
5
0
7
8
0
6
5
9
0
.
9
5
(
0
.
6
8
–
1
.
3
2
)
0
.
7
9
(
0
.
6
6
–
0
.
9
6
)
1
.
3
9
(
1
.
0
0
–
1
.
9
2
)
0
.
9
2
(
0
.
8
0
–
1
.
0
5
)
r s 9 2 8 2 5 6 4
A
/
A
4
3
2
4
6
4
1
4
7
1
1
4
1
7
1
0
0
4
1
3
5
5
2
9
0
7
3
2
3
6
1
.
0
0
0
.
7
0
9
1
.
0
0
0
.
0
5
2
1
.
0
0
0
.
7
1
9
1
.
0
0
0
.
1
2
3
A
/
G
1
2
9
1
3
6
3
0
1
3
4
1
2
4
5
3
6
9
6
7
5
8
4
6
1
.
0
3
(
0
.
7
8
–
1
.
3
7
)
1
.
1
8
(
1
.
0
0
–
1
.
4
1
)
1
.
1
2
(
0
.
9
3
–
1
.
3
4
)
1
.
1
2
(
1
.
0
0
–
1
.
2
6
)
G
/
G
1
0
1
2
2
1
2
4
1
8
1
3
4
9
4
9
1
.
2
0
(
0
.
5
1
–
2
.
8
3
)
1
.
2
0
(
0
.
6
7
–
2
.
1
7
)
0
.
5
3
(
0
.
2
6
–
1
.
0
9
)
0
.
9
2
(
0
.
6
2
–
1
.
3
8
)
a
N
u
m
b
e
r
s
m
a
y
n
o
t
a
d
d
u
p
t
o
1
0
0
%
o
f
s
u
b
j
e
c
t
s
d
u
e
t
o
g
e
n
o
t
y
p
i
n
g
f
a
i
l
u
r
e
.
b
M
o
d
e
l
s
w
e
r
e
a
d
j
u
s
t
e
d
f
o
r
a
g
e
,
s
e
x
a
n
d
(
i
n
t
h
e
c
o
m
b
i
n
e
d
p
o
p
u
l
a
t
i
o
n
)
s
t
u
d
y
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
2
7
8
4
.
t
0
0
2
Polymorphisms of ABCB1 and Colon Cancer
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32784Results in the discovery set
The analysis of the 28 tagging SNPs in the Czech population
did not reveal any statistically significant association (using the
threshold of p=0.003). The distribution of the genotypes of the 28
SNPs in the Czech population and their odds ratios (ORs) for
association with CRC risk are shown in Supplementary Table S2.
Associations of three polymorphisms with CRC risk at the
conventional level of p,0.05 were observed in the DACHS study.
Carriers of the rs1202168_T and rs868755_T alleles had an
increased risk of CRC (ORhet=1.20, 95%CI 1.04–1.40,
ORhom=1.23, 95%CI 1.01–1.48, Ptrend=0.016, and ORhet=1.17,
95%CI 1.00–1.36, ORhom=1.22, 95%CI 1.01–1.48,
Ptrend=0.029, respectively) while individuals bearing the
rs1045642_C allele had a decreased risk of CRC (ORhom=0.79,
95%CI 0.66–0.96, Ptrend=0.022, Supplementary Table S3).
Results of the replication study
Four SNPs which showed a statistically significant (rs1202168,
rs1045642, rs868755) or borderline significant (rs9282564) associ-
ation in the German discovery set were typed in an additional set of
CRC cases and healthy controls from Germany. None of the SNPs
showed a statistically significant association with CRC risk in the
replication set or in the combined dataset. The distribution of the
genotypes of the four SNPs typed in all the subjects of this study and
their ORs for association with CRC risk are shown in Table 2.
Haplotype analysis
None of the haplotypes showed a statistically significant
association after correction for multiple testing. When testing the
haplotypes in the pooled population, none showed any statistically
significant association with CRC risk at the conventional threshold
of P=0.05. The distribution of ABCB1 haplotypes for the
functional SNPs and risk of CRC are shown in supplementary
table S4.
Discussion
Although functional data regarding ABCB1 SNPs are not totally
consistent, some of them have reported to be involved with an
enhanced efflux transporting ability [23,42,53]. Likewise, several of
these functional polymorphisms have been found to be associated
withCRCriskfactors suchasulcerative colitis orobesity [54,55,56].
The present study attempted to evaluate systematically the role of
common ABCB1 polymorphisms on CRC risk.
Several studies have investigated the possible role of genetic
variants in ABCB1 and risk of colorectal disease, mostly focusing on
C3435T (rs1045642) and on 2677G.T/A (rs2032582). Overall
these studies are heterogeneous in terms of size, number of SNPs
tested, methodology used and ethnicity. C3435T was found to be
associated with disease risk in several case-control studies
[33,57,58,59] while others did not find any statistically significant
associations [34,60] The polymorphism variant 2677G.T/A
(rs2032582) in exon 21 has also been found associated with CRC
risk [26,45,59], although not in all studies [34]. Anderson and
colleagues also tested the possible association of rs3789243 in two
distinct studies. They found an association in a Danish population
but did not find anything in a study based on Norwegian subjects
[3,57]. In this study we have genotyped rs3789243 and we did not
observe any statistically significant association.
Three ABCB1 variants (rs1202168, rs1045642 and rs868755)
were found to be associated with CRC risk in the DACHS study
population. Carriers of the rs1202168_T and rs868755_T alleles
showed an increased risk of CRC, while individuals bearing the,
rs1045642_C allele (also referred to as C3435 in previous studies)
showed a decreased risk for CRC. The results regarding
rs1202168 and rs868755 are novel, although rs2032582 and
rs868755 are in high LD (r
2=0.85), while the results regarding
rs1045642 are in concordance with several other studies that
found that the C3435T polymorphism contribute to risk of CRC.
In agreement with our results, Kurzawski and co-workers found
that carriers of the variant allele of the C3435T polymorphism had
an increased risk of CRC while carriers of CC genotype had the
lowest risk for CRC [33]. In addition, several haplotypes
containing the rs1045642_C allele have been associated with
slower CRC progression [30]. Kimchi-Sarfaty and co-workers also
suggested that this silent polymorphism affect the post-translation-
al protein folding and its transport activities [61].
However, current data regarding the influence of ABCB1 SNPs on
CRC risk are conflicting and, although three SNPs in the DACHS
population showed a statistically significant association with CRC,
none of them showed the same trend in the replication study.
In addition, it is worth to note that our replication study
performed in a Northern German population from Kiel showed
that the rs1045642_C allele was associated with an increased,
albeit not statistically significant, risk for CRC, i.e., an opposite
effect to the one found in the DACHS study. These results
obtained in the Northern Germans are in concordance with those
previously published in a Danish population [57]. Consequently, it
might be conceivable to think that the interplay between genetic
variants and environmental factors could modify the risk of CRC.
Genome-wide association studies (GWAS) of CRC have con-
firmed the hypothesis that part of the heritable risk for this disease is
caused by common, low-risk variants and have identified various
common variants associated with CRC risk [62,63,64,65,66] but
none of the GWAS reported polymorphisms in the ABCB1 gene as
major CRC risk factors. However, since only associations significant
at the genome-wide level (typically p,10
27) arereported inGWASit
is not possible to exclude that ABCB1 polymorphisms were associated
with CRC risk but were not reported due to the strict statistical
threshold used. It has been indeed documented that GWAS are
prone to reporting false negative results [67].
To our knowledge, the present study is one of the largest studies
to address the potential association between ABCB1 polymor-
phisms and CRC risk. In this study we had a statistical power
greater than 80% to detect an association for a log additive model
with OR=1.45 at a=0.001 for the tagSNPs discovery set
(MAF=0.30), OR=1.23 for the functional discovery set
(MAF=0.30) and OR=1.16 for the joint analysis (MAF=0.30).
Moreover the hybrid tagging/functional approach facilitated a
comprehensive analysis of common variants in the ABCB1 gene
region in two well-defined and homogeneous study populations
with a sufficient size. In addition, we used a large population-based
study carried out in the same ethnic group for replication.
Nonetheless, this study has some potential limitations. First, the
large number of test performed could lead to chance finding and
indeed, adding the correction for multiple testing none of the SNPs
showed statistically significant associations. Moreover, even if the
three populations are of Caucasian origin, a possible heterogeneity
between them could still be present. Finally in this report we did
not consider rare variants either as SNPs or CNVs.
In conclusion in this report we cannot completely exclude a
role, albeit minor, for ABCB1 gene variants and CRC risk.
Supporting Information
Figure S1 Shows in detail the number of SNPs and subjects
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